Implantology in the Medically Compromised Patient: Diabetes, Osteoporosis, Bisphosphonate Therapy and Anticoagulants

The growing prevalence of chronic conditions in the elderly and adult population — implantology's main demographic target — requires thorough knowledge of the interactions between systemic disease and osseointegration. Preoperative medical assessment in implantology isn't a bureaucratic formality: it's a clinical component that can change protocol choice, procedure timing, perioperative drug prescribing, and long-term prognosis. The four systemic conditions with the greatest documented impact on implantology are diabetes mellitus, osteoporosis, therapy with bone antiresorptive drugs (bisphosphonates, denosumab), and anticoagulant/antiplatelet therapy.

Diabetes mellitus affects osseointegration through multiple mechanisms: reduced neutrophil chemotaxis and bactericidal function increases susceptibility to early peri-implant infections; hyperglycemia creates an environment unfavorable to cell proliferation and collagen synthesis; diabetic microangiopathy reduces vascularization of peri-implant bone tissue. Clinical data on diabetes's impact are consistent but not uniform: Chrcanovic et al.'s meta-analysis (J Oral Rehabil, 2014) on 1,424 implants in diabetic patients documented a failure rate of 4.7% vs. 2.5% in non-diabetic controls (OR 1.84, 95% CI 1.24-2.73). Glycemic control is the crucial modifiable factor: patients with HbA1c <7% show survival rates comparable to non-diabetics, while HbA1c >9% is associated with triple the failure risk. The conventional threshold of HbA1c <7% (or ≤8% in more recent guidelines for elderly patients) as a prerequisite for elective implantology is supported by sufficient evidence to be recommended in clinical practice.

Osteoporosis — characterized by reduced bone mineral density (BMD) and microarchitectural deterioration of bone tissue — is the most prevalent condition in older age and the systemic condition raising the most concern among clinicians regarding implant implications. Paradoxically, evidence on the impact of diagnosed osteoporosis on implant survival rates is less negative than commonly expected: Holahan et al.'s systematic review (Int J Oral Maxillofac Implants, 2008) found no statistically significant differences in survival rates between osteoporotic patients and controls. The biological rationale is that osteoporosis mainly reduces trabecular quality in the appendicular skeleton, while the jaws — with a relatively preserved cortical component — show less pronounced changes. However, D3-D4 bone quality, more common in osteoporotic patients, requires specific technical adaptations: site underpreparation, macro-retentive implants, reduced insertion torque.

Bone antiresorptive drugs — bisphosphonates (alendronate, zoledronate) and anti-RANK-L antibodies (denosumab) — are prescribed for treating osteoporosis, multiple myeloma, and bone metastases. Medication-related osteonecrosis of the jaw (MRONJ) is the most feared complication in implantology: it presents as persistent bone exposure for >8 weeks without prior irradiation or local bone pathology. MRONJ incidence in osteoporosis patients on oral bisphosphonate therapy is estimated at <1% for implant procedures, with variable data across observational studies. The AAOMS (American Association of Oral and Maxillofacial Surgeons) recommends suspending oral bisphosphonates for 2 months before and 3 months after surgery in high-risk patients (therapy >4 years, concurrent corticosteroids, CTX <100 pg/mL), considering drug suspension in agreement with the prescribing physician. Long-term vigilance — with six-monthly visits — is mandatory for early detection of early MRONJ signs in at-risk patients.

Anticoagulant therapy (warfarin, NOACs: rivaroxaban, apixaban, dabigatran) and antiplatelet therapy (aspirin, clopidogrel) are common in the elderly population seeking implantology. Perioperative management has undergone significant revision in recent years: suspending NOACs is no longer routinely recommended for low-complexity implant surgery, with growing evidence that continuing therapy doesn't significantly increase bleeding risk if combined with adequate local hemostatic measures (intra-alveolar resorbable collagen, interrupted sutures, post-operative compression). The target INR for patients on warfarin is ≤3.5 for standard implant surgery; higher values require assessment by the treating physician before the procedure. Communication with the cardiologist/internist is essential: the decision to suspend or modify anticoagulant therapy rests with the prescribing physician, not the dentist.

Structured pre-implant systemic assessment — through a standardized history investigating diabetes (with a recent HbA1c request), bone disease and antiresorptive drugs (with serum CTX measurement if indicated), anticoagulant/antiplatelet therapies, history of radiotherapy, immunosuppression — is the best guarantee for preventing systemic complications. The ITI consensus document (Bornstein et al., Clin Oral Implants Res, 2018) provides risk stratification into four categories (low, moderate, high risk, absolute contraindication) for the main systemic conditions, with operational recommendations for each category. An implant dentist operating on systemically compromised patients without a structured medical assessment exposes themselves to significant clinical and legal liability.